A little about virotherapy:
2 years ago, I was diagnosed with oncological disease of stage II, and a surgical treatment was performed.
Even though cancer treatment usually includes chemotherapy, council suggested to use hormonal therapy, obviously judging by the general health condition and existing co-morbidities. When I started hormonal therapy, general health condition rapidly deteriorated: dizziness, joint pain, exacerbated manifestations of bronchial asthma (asthma attacks almost every night). Due to markedly unsatisfactory quality of life, together with the chemotherapist – oncologist we decided not to use this medication.
I was not satisfied with the idea of remaining without any protection. When I read literature, surfed the internet, I learned about the use of oncolytic virotherapy in treatment of tumours on the basis of cytolytic activity of medication, while simultaneously stimulating immunity of the body in various ways in order to activate it to battle the malignant activity of cancer.
I had an opportunity to start virotherapy treatment which I have been continuing already for 1.5 years. Health condition and quality of life have improved during the treatment; examinations do not show data on disease activity and spread, and I can work at a paid job.
Considering the above-mentioned effect mechanisms of virotherapy and by continuing clinical research and summarising the results, according to discovered indications these medications should be included in complex treatment of oncological diseases.
Currently the idea of entrusting observation of oncological patients to general practitioners is being considered. I believe that many doctors are not informed about the potential of virotherapy in oncology. Therefore, lectures on oncolytic viruses and use of virotherapy in treatment of cancer should be included in interdisciplinary conferences of the doctors association.
Irēna Ausma Rudņeva
Internist / Cardiologist / Expert Doctor / former assistant professor at Riga Stradiņš University